INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 418m ago
HOUSE PTR18m ago
SEC 13F17m ago
ROBINHOOD CHAIN17m ago
SEC FORM 4/Tax withholdingVerified dataRule 10b5-1 plan

Abernethy Matt reported NBIX

Chief Financial Officer · NEUROCRINE BIOSCIENCES INC · Common Stock

Side
F
Value
$423K
Shares
2,709
Price
$156.22
Executed
Sep 11, 2026
Disclosed
Sep 15, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 11 executedSep 15, 2026 disclosed

NBIX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+11 / 25

$423K reported value · 6.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NBIX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    27
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$330K
    2,112 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    21
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,914 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    15
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    13
    DI
    Delaet IngridChief Regulatory Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    4,483 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    25
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$363K
    2,311 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    3
    AM
    Abernethy MattChief Financial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award · 10b5-1 plan
    		A—
    5,020 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding · 10b5-1 plan
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    13
    CJ
    Cooke JulieChief Human Resources Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    19
    CJ
    Cooke JulieChief Human Resources Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$302K
    1,936 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    15
    DI
    Delaet IngridChief Regulatory Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$378K
    2,419 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    3
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Grant or award · 10b5-1 plan
    		A—
    3,587 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    18
    BW
    Boyer David W.Chief Corp. Affairs Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$130K
    826 sh
    		Sep 14, 2026Sep 15, 2026
    traded Sep 14, 2026
    		+1dSEC FORM 4

    Evidence

    21
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$333K
    2,154 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    6
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M$138K
    3,194 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BE
    Benevich EricChief Commercial Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    3,194 sh
    		Sep 9, 2026Sep 10, 2026
    traded Sep 9, 2026
    		+1dSEC FORM 4

    Evidence

    12
    OJ
    Onyia JudeChief Scientific Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Gift
    		G—
    2,441 sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    21
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise
    		M—
    3,212 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Option exercise
    		M—
    3,212 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    15
    KC
    Keswani Sanjay ChandruChief Medical Officer
    NBIXNEUROCRINE BIOSCIENCES INC
    Tax withholding
    		F$268K
    1,733 sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001724097-26-000010
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 11, 2026
    Published
    Sep 15, 2026
    Ingested by INSIDER
    Nov 5, 02:17 UTC
    Last re-read
    Nov 5, 02:17 UTC

    Extracted facts

    Filer
    Abernethy Matt
    Role
    Chief Financial Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    NEUROCRINE BIOSCIENCES INC
    Ticker
    NBIX
    Shares
    2,709
    Price per share
    $156.22
    Value
    $423,200
    Execution date (reported)
    Sep 11, 2026
    Owned after transaction
    45.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 2,709
    • Price: $156.22

    = $423,200

    What this establishes

    Abernethy Matt filed this Form 4 reporting a tax withholding of NBIX on Sep 11, 2026. It became public on Sep 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Abernethy Mattcik:0001724097
    Issuer
    NEUROCRINE BIOSCIENCES INCcik:0000914475

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.